TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03036800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda
Description: standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialist Obesity Management Services
Description: Specialist Obesity Management Services standard of care
Study: NCT03390036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: Triamcinolone Hexacetonide
Study: NCT03036800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialist Obesity Management Services
Description: Specialist Obesity Management Services standard of care
Study: NCT02142985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9% Intravenous
Description: vascular filling with 500 ml of crystalloid solution (sodium chloride 0.9%) over 30 minutes
Study: NCT04615741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Yoga
Description: One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Psychotherapy
Description: Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
Study: NCT02421003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: heart surgery
Study: NCT01048489

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education in the high school
Description: (12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco.
Study: NCT02392832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fourstar® granule, 90 day and 180 day briquettes Bti/Bs
Description: In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, a total of 34 clusters in the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs.
Study: NCT03513523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 1 NRPT
Description: Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 2 NRPT
Description: Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
Study: NCT02831868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAVAI
Description: implantation of the HAVAI device to correct the IMA angle
Study: NCT02312986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
Study: NCT02447107

Intervention type: OTHER
Intervention: Electronic Diary
Description: The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.

Intervention type: OTHER
Intervention: Questionnaire
Description: Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
Study: NCT03513523

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group 3 Placebo
Description: Four placebo capsules will be taken once daily in the morning for 26 weeks.
Study: NCT01681368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant (TL32711)
Description: 47mg/m\^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
Study: NCT03464214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neck Muscle Vibration
Description: Local vibration device applied on neck muscles for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Stabilization Exercises
Description: Cervical stabilization exercises performed by healty individuals for 8 weeks
Study: NCT01466777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional surgery type
Description: Traditional laparoscopic surgery for endometrial cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic surgery
Description: Robotic assisted laparoscopic surgery for endometrial cancer
Study: NCT03125291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridges 4-week Program
Description: Participants receive 4, 2-hour sessions over a 6-week period.
Study: NCT01902719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) Intervention
Description: Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) Intervention
Description: Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) Intervention
Description: Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
Study: NCT04527250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: ASC41,1mg/table;5mg/table
Study: NCT01445626

Intervention type: DRUG
Intervention: dexamethasone intravitreal implant 0.7 mg
Description: Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
Study: NCT00554983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant birch pollen allergen
Description: subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
Study: NCT01490515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-invasive metabolomic profiling
Description: non-invasive metabolomic profiling of IVF human embryos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: morphological evaluation
Description: Simple microscopic observation of embryos and evaluation of morphological characteristics
Study: NCT04082182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell immunotherapy
Description: Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific DTH
Description: Intradermal injection of 1 x 10E6 MIDRIX4-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Control DTH
Description: Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
Study: NCT00650221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Single-dose 80 mg immediate-release oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Single-dose 80 mg immediate-release tablet
Study: NCT02703961

Intervention type: DRUG
Group type: OTHER
Intervention: concurrent chemotherapy with cisplatin
Description: in experimental group: cisplatin 60mg/m2, d1,d22;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy with cisplatin
Description: in experimental group: cisplatin 60mg/m2, d1,d22;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy with docetaxel
Description: in experimental group: docetaxel 60mg/m2, d1,d22;

Intervention type: RADIATION
Group type: OTHER
Intervention: pelvic radiotherapy
Description: external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
Study: NCT04527250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: ASC41,1mg/table;5mg/table

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: ASC41,1mg/table;5mg/table

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: ASC41,1mg/table;5mg/table

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41
Description: ASC41,1mg/table;5mg/table

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC41 placebo
Description: ASC41 placebo,1mg/table;5mg/table
Study: NCT03060577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Study: NCT04527250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC41 placebo
Description: ASC41 placebo,1mg/table;5mg/table

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC41 placebo
Description: ASC41 placebo,1mg/table;5mg/table

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC41 placebo
Description: ASC41 placebo,1mg/table;5mg/table
Study: NCT02703961

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pelvic radiotherapy
Description: external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.

Intervention type: RADIATION
Group type: OTHER
Intervention: brachytherapy
Description: CT/MRI guided brachytherapy or x-ray guided brachytherapy
Study: NCT03060577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
Study: NCT00986193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transapical Aortic Valve Implantation
Description: Insertion of a stent valve using catheter-based technique through a mini thoracotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Aortic Valve Surgery
Description: Operation using heart-lung machine, with insertion of a biological artificial heart valve
Study: NCT04251312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Hygiene Education and Oral Hygiene Packets
Description: Patients will be educated on oral hygiene and will be given packets containing toothpaste, mouth rinse, floss and a toothbrush
Study: NCT04527250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC41 placebo
Description: ASC41 placebo,1mg/table;5mg/table
Study: NCT00523666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine (Reminyl®)
Description: 8mg - 24mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Galantamine (Reminyl®)
Description: Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg
Study: NCT01927289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Brachial Plexus vs Distal Forearm Block
Description: Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.~Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
Study: NCT02641704

Intervention type: BEHAVIORAL
Intervention: Multidisciplinary program
Description: Coordinated multidisciplinary program
Study: NCT02333331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimagrumab
Description: Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimagrumab
Description: Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimagrumab
Description: Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
Study: NCT01902719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Skills Training
Description: Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
Study: NCT00134537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interspinous process and dynamic stabilization
Description: Interspinous process and dynamic stabilization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Care
Description: Medication, exercise and spinal injections
Study: NCT00842062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoScience Tissue Remodeling Device
Description: Percutaneous treatment with the MyoScience device
Study: NCT01728636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: intravenous administration of bolus and infusion for duration of surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: intravenous administration of bolus and infusion for duration of surgical procedure
Study: NCT01253564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg b.i.d. orally
Study: NCT01442285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized, motivational messages
Description: A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
Study: NCT02676622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mobilization of stem cells to prepare for Leukapheresis
Description: Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leukapheresis- Collection of stem cells
Description: Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight.
Study: NCT01186835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combination Botulinum Toxin A and Hyaluronic Acid
Description: One side of subject's face will randomly be assigned combination treatment.
Study: NCT02703961

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: CT/MRI guided brachytherapy or x-ray guided brachytherapy
Study: NCT01186835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Description: Other side of subjects face with receive Botulinum Toxin A treatment alone.
Study: NCT03420482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT) oral capsules
Description: Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
Study: NCT02703961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy with cisplatin and docetaxel
Description: cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
Study: NCT02505139

Intervention type: OTHER
Intervention: the number of circulating tumor cells
Study: NCT03188328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AvidinOX
Description: AvidinOX vial containing 22.5 mg AvidinOX~+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-ST2210
Description: 177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-ST2210
Description: Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
Study: NCT03228199

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Will be deferred to receive spectacles as above, after the 12 week evaluation period.
Study: NCT03420482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
Study: NCT04161898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib will be administered as oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib will be administered as oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Placebo for upadacitinib will be administered as oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone will be administered as oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone will be administered as oral tablet
Study: NCT01945762

Intervention type: DRUG
Intervention: Vandetanib 300 mg
Description: Vandetanib commercial tablets
Study: NCT00343681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (split virion)
Description: 0.5 mL, Intramuscular
Study: NCT01634139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low dose QD
Description: 2 actuations once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium high dose QD
Description: 2 actuations once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 actuations once daily in the evening